CARLS(BA)D, Calif., Nov. 30, 2020 /PRNewswire/ –Ionis Prescription drugs, Inc., (NASDAQ: IONS) as we speak introduced that the biopharmaceutical firm AstraZeneca has initiated a Section 2b scientific trial of ION449 (AZD8233), an investigational antisense drugs designed to cut back blood levels of cholesterol in sufferers with dyslipidemia by focusing on proprotein convertase subtilisin/kexin kind 9 (PCSK9), an vital regulator of low-density lipoprotein ldl cholesterol (LDL-C). PCSK9 is an enzyme that controls the variety of LDL receptors on the floor of cells. Folks with genetic variations that scale back PCSK9 operate have decrease LDL-C ranges within the blood and a decrease threat for main cardiovascular occasions. ION449 is a LIgand Conjugated Antisense (LICA) drugs being developed by AstraZeneca as a part of a collaboration between Ionis and AstraZeneca.
The Section 2b, randomized, double-blind, placebo-controlled trial will enroll roughly 108 individuals, aged 18-75, who’ve LDL-C ranges between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin remedy as outlined by the American Faculty of Cardiology/American Coronary heart Affiliation (ACC/AHA) tips on blood ldl cholesterol administration. The first goal is to evaluate the impact of various doses of ION449 on LDL-C in comparison with placebo at Week 12 in sufferers taking baseline statin remedy. The research will consider three dose ranges of ION449 versus placebo, all administered as soon as a month by subcutaneous injection. Security and tolerability might be evaluated together with various secondary endpoints. Study extra concerning the trial at: https://clinicaltrials.gov/ct2/present/NCT04641299.
In a Section 1 research reported on the American Coronary heart Affiliation (AHA) Scientific Periods on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent imply reductions in circulating plasma PCSK9 and LDL-C ranges of >90 % and as much as 70 %, respectively, in topics who had a baseline LDL-C between 100 and 190 mg/dL with out concomitant statin remedy.1 Doses as much as 120 mg had been evaluated. ION449 was noticed to be protected and well-tolerated in any respect dose ranges.
“Outcomes from the Section 1 research confirmed that ION449 potently reduces PCSK9 and LDL ldl cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C discount, supporting bigger scientific trials that at the moment are underway to additional consider efficacy and security,” stated Sotirios “Sam” Tsimikas, M.D., senior vice chairman, scientific improvement and cardiovascular franchise chief at Ionis. “The rising proof supporting Ionis’ superior LICA expertise in heart problems holds promise for more practical approaches to decrease LDL-C and to deal with heart problems, the main reason for demise worldwide.”
Dr. Tsimikas will present an replace on Ionis’ cardiovascular applications throughout Ionis’ Digital Investor Day, Dec. 7, 2020, starting at 12 p.m. EST.
Ionis earned a milestone cost of $20 million from AstraZeneca for the Section 2b scientific trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential remedies for kidney illness, cardiometabolic illness and most cancers.
About Ionis Prescription drugs, Inc.
Because the chief in RNA-targeted drug discovery and improvement, Ionis has created an environment friendly, broadly relevant, drug discovery platform referred to as antisense expertise that may deal with illnesses the place no different therapeutic approaches have confirmed efficient. Our drug discovery platform has served as a springboard for actionable promise and realized hope for sufferers with unmet wants. We created the primary and solely authorised therapy for all sufferers, kids and adults with spinal muscular atrophy, in addition to the world’s first RNA-targeted therapeutic authorised for the therapy of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all of the sufferers we’ve got but to achieve with a pipeline of greater than 40 novel medicines designed to doubtlessly deal with a broad vary of illness, together with neurological, cardio-renal, metabolic, infectious, and pulmonary illnesses.
To study extra about Ionis go to www.ionispharma.com and observe us on Twitter @ionispharma.
Ionis’ Ahead-looking Assertion
This press launch consists of forward-looking statements relating to Ionis’ enterprise and the therapeutic and industrial potential of ION449 (AZD8233), Ionis’ applied sciences and merchandise in improvement. Any assertion describing Ionis’ targets, expectations, monetary or different projections, intentions or beliefs is a forward-looking assertion and needs to be thought of an at-risk assertion. Such statements are topic to sure dangers and uncertainties, together with these associated to the affect COVID-19 might have on our enterprise, and together with however not restricted to these associated to our industrial merchandise and the medicines in our pipeline, and notably these inherent within the means of discovering, growing and commercializing medicines which can be protected and efficient to be used as human therapeutics, and within the endeavor of constructing a enterprise round such medicines. Ionis’ forward-looking statements additionally contain assumptions that, in the event that they by no means materialize or show appropriate, might trigger its outcomes to vary materially from these expressed or implied by such forward-looking statements. Though Ionis’ forward-looking statements mirror the great religion judgment of its administration, these statements are based mostly solely on information and elements at present recognized by Ionis. Consequently, you might be cautioned to not depend on these forward-looking statements. These and different dangers regarding Ionis’ applications are described in extra element in Ionis’ annual report on Kind 10-Okay for the yr ended December 31, 2019, and the latest Kind 10-Q quarterly submitting, that are on file with the SEC. Copies of those and different paperwork can be found from the Firm.
On this press launch, except the context requires in any other case, “Ionis,” “Firm,” “we,” “our,” and “us” refers to Ionis Prescription drugs and its subsidiaries.
Ionis Pharmaceuticalsä is a trademark of Ionis Prescription drugs, Inc.
1 Medical research (NCT03593785), sponsored by AstraZeneca.
View unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/ionis-announces-astrazenecas-initiation-of-the-phase-2b-clinical-study-of-its-antisense-medicine-targeting-pcsk9-to-lower-ldl-cholesterol-301181930.html
SOURCE Ionis Prescription drugs, Inc.